A coronavirus vaccine developed by a U.S company known as "Moderna" and the National Institute of Health, a medical research institution is expected to become the first in the U. S to enter the final stage of clinical testing.
Preliminary outcomes claimed it is safe and have the ability to stimulate an immune response against the coronavirus.
However, Moderna is planning to enter the 3rd phase of its clinical trial on the 27th of July this year and they are also hoping to test the vaccine on thirty thousand (30,000) individuals.
The 45 volunteers who received the vaccine as an experiment for trial in the first phase were found to be having antibodies in their blood that can fight against the coronavirus. These volunteers also had no serious side effects, and the volunteers however were youths.
Speaking to members of the press, the U.S government health advisor Anthony Fauci said there are twenty-three (23) coronavirus vaccine candidates currently around the world.
Wow!! This indeed is a good news
Content created and supplied by: Zammyclare (via Opera News )
Opera News is a free to use platform and the views and opinions expressed herein are solely those of the author and do not represent, reflect or express the views of Opera News. Any/all written content and images displayed are provided by the blogger/author, appear herein as submitted by the blogger/author and are unedited by Opera News. Opera News does not consent to nor does it condone the posting of any content that violates the rights (including the copyrights) of any third party, nor content that may malign, inter alia, any religion, ethnic group, organization, gender, company, or individual. Opera News furthermore does not condone the use of our platform for the purposes encouraging/endorsing hate speech, violation of human rights and/or utterances of a defamatory nature. If the content contained herein violates any of your rights, including those of copyright, and/or violates any the above mentioned factors, you are requested to immediately notify us using via the following email address operanews-external(at)opera.com and/or report the article using the available reporting functionality built into our Platform See More